🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I voted for my family, for the women of my family, specially my newborn baby girl 🩷. I voted for a place of opportunity for all, where our common goals are bigger than what divide us. I voted hoping for a place that recognizes the struggle of those suffering the most. 💙

Speechless, not to say the least. How much this decision says about who we are. What legacy are we setting up for those who come after us? Nevertheless, let’s take time to support each other, share our grievances and fears. But also let’s ge ready to push back and persevere.

Heading to Society for Immunotherapy of Cancer conference #SITC24. Thrilled to present work on our Fc-engineered anti-CD40 antibody and induction of tertiary lymphoid structures and systemic immunity in patients with metastatic cancer. Tomorrow at 12:30. See you there!

Hope to see the science/MedOnc community at 👇 ☁️ 🦋 same handle! See you there!

Thrilled to present updates on our work in this session with amazing and inspiring leaders in the field. Please join us this Thursday! sitcancer.org/education/webi…

🎥Juan C Osorio MD of Memorial Sloan Kettering Cancer Center discusses a Phase I study on 2141-V11, an anti-CD40 antibody designed to enhance FcγRIIB binding, aiming to improve tumor response & reduce toxicity: ➡️ow.ly/mXuh50Us29s⬅️ Society for Immunotherapy of Cancer #SITC24 #ImmunoOnc #Oncology #CTSM

Online now: Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion dlvr.it/TH0W1M

I am pleased to announce our latest review article published in Trends in Cancer ! In this review, we summarize recent advances in myeloid-oriented therapeutics for cancer. Myeloid cell modulation is a growing frontier in cancer therapy. authors.elsevier.com/a/1kPgF8Z12yXj…

So important to spread all the effort that goes through NIH grant submissions, and the ramifications of holding these efforts at so many levels.

Thrilled to present at AACR annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody. #AACR25

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at National Cancer Institute Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity cassyni.com/events/Eg84FXZ…

Interested in assessing antibody-dependent cellular phagocytosis by primary macrophages? Here is a practical and optimized protocol developed by dedicated and talented members of the lab, enjoy! sciencedirect.com/science/articl…

Excited for tomorrow! #AACR2025

Juan C Osorio MD presents his beautiful translational work on CD40 agonist 2141-V11. #TLS formation implicated response in #bladdercancer. ➡️Keep Dr. Osorio on your radar. He is a 🌟. He will be starting his own lab as an independent investigator soon! #K08 #AACR25 #AACRMBCO

Great AACR clinical trial plenary on Biologics and T cell Engagers chaired by Jedd Wolchok #crystalmackall with outstanding talks around early phase data in solid tumors by Hope Rugo Jason Luke, MD, FACP and many others

Great discussion today at #AACR25 on myeloid targeting therapies and induction of immune-privilege sites within the TME through biologics. Thank you to Jedd Wolchok and Crystal Mackall for moderating the session, and Sangeeta Goswami, MD,PhD for the amazing discussion on this topic.

Biologics and T-cell Engagers: Researchers shared updates on cutting-edge immunotherapies during this #AACR25 Clinical Trials Plenary Session. Read a recap in AACR Annual Meeting News: brnw.ch/21wSCNn Juan C Osorio MD

Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org

We are looking for an associate research scientist and lab manager for our translational cancer immunology lab at Yale. Please email ([email protected]) or DM me to apply. Full information about the job and the requirements can be found here: jobrxiv.org/job/yale-schoo… Pls RT!

Cutting edge research by the Glickman lab. Intersecting areas of infectious disease and oncology leading to a better understanding of BCG activity against #bladdercancer Society of Urologic Oncology UrologyMSK Memorial Sloan Kettering Cancer Center